DOCSLIB.ORG

In Vitro Investigation of Synergy Among Fosfomycin and Parenteral Antimicrobials Against Carbapenemase-Producing Enterobacteriaceae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Vitro Investigation of Synergy Among Fosfomycin and Parenteral Antimicrobials Against Carbapenemase-Producing Enterobacteriaceae Diagnostic Microbiology and Infectious Disease 95 (2019) 216–220 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae Lindsay M. Avery a, Christina A. Sutherland a, David P. Nicolau a,b,⁎ a Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA b Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA article info abstract Article history: Intravenous fosfomycin is undergoing clinical development in the United States for treatment of complicated Received 11 July 2018 urinary tract infections (cUTIs) and may be prescribed as a component of dual antibiotic regimens against Received in revised form 6 May 2019 carbapenemase-producing Enterobacteriaceae (CPE). Fosfomycin, aztreonam, cefepime, ceftazidime, ceftazi- Accepted 16 May 2019 dime/avibactam, ceftolozane/tazobactam, meropenem, piperacillin/tazobactam, and tobramycin minimum in- Available online 25 May 2019 hibitory concentrations (MICs) were determined by gradient diffusion strip (GDS) against CPE isolates (N = Keywords: 49). The GDS cross method was used to assess antibiotic interactions between fosfomycin and the aforemen- Enterobacteriaceae tioned parenteral antibiotics. The resultant fractional inhibitory concentration index was used to classify interac- Carbapenemase tions. Fosfomycin-containing combinations were evaluated only if nonsusceptible to the second agent. The Synergy fosfomycin MIC50 was ≥1024 mg/L by GDS. Synergy or additivity was detected in 80 (22%) fosfomycin- Fosfomycin containing combinations. Antagonism was not observed. Ceftolozane/tazobactam most frequently displayed synergy [8 (16.3%) isolates]. When CPE are isolated, clinical laboratories should consider performing GDS synergy tests to identify favorable antibiotic interactions. © 2019 Elsevier Inc. All rights reserved. 1. Introduction pharmacokinetic properties such as negligible protein binding and high tissue penetration allow for a potential utility in combination anti- Fosfomycin is a broad-spectrum antibiotic available as an intrave- biotic regimens for the treatment of MDR pathogens even in cases of nous (IV) formulation, fosfomycin disodium, for treatment of various deep-seated infection (Grabein et al., 2017). systemic infections in several European countries and Japan (Falagas Pharmacodynamic optimization of antimicrobial regimens, which et al., 2016; Grabein et al., 2017). In the United States, fosfomycin is ap- may include the use of combination therapy with 2 or more agents, is proved for treatment of uncomplicated urinary tract infection, but it is especially important in the treatment of CPE and other MDR Gram- available only as an oral formulation (Kaye et al., 2017, Monurol Pre- negative pathogens (Kollef et al., 2011; Monogue et al., 2016). The gra- scribing Information, 2007). However, IV fosfomycin is now being in- dient diffusion strip (GDS) cross method is an in vitro method used to vestigated in U.S. clinical trials to support its use in the treatment of investigate antibiotic interactions in terms of the fractional inhibitory complicated urinary tract infections (NCT02753946). concentration index (FICI), and it has been used to examine the activity Infections caused by multidrug-resistant (MDR) pathogens such as of dual antibiotic combinations against MDR organisms such as carbapenemase-producing Enterobacteriaceae (CPE) pose therapeutic Acinetobacter baumannii (Nageeb et al., 2015), Enterobacteriaceae challenges. Due primarily to acquisition of multiple broad-spectrum re- (Monogue et al., 2017; Samonis et al., 2012; White et al., 1996), Neisseria sistance mechanisms, a single agent (e.g., β-lactam) is unlikely to pro- gonorrhoeae (Wind et al., 2015), Pseudomonas aeruginosa (Samonis vide adequate empiric coverage of these pathogens in serious et al., 2012; White et al., 1996), and Stenotrophomonas maltophilia systemic infections (Kollef et al., 2011; Pogue et al., 2015). Fortunately, (Church et al., 2013). An anticipated role for IV fosfomycin in the U.S. worldwide clinical use of fosfomycin has remained infrequent since its will be as a component of dual antibiotic therapy when prescribed original discovery in 1969 (Grabein et al., 2017), and thus, the com- for CPE infections, especially those outside of the urinary tract. pound has retained activity against many MDR pathogens, including Thus, the purpose of the present study was to characterize antibiotic in- some CPE (Falagas et al., 2010,2016;. Furthermore, favorable teractions between fosfomycin and nonsusceptible antibiotics (aztreo- nam, cefepime, ceftazidime, ceftazidime/avibactam, ceftolozane/ tazobactam, meropenem, piperacillin/tazobactam, and tobramycin) ⁎ Corresponding author. Tel.: +860-972-3941; fax: +860-545-3992. among a genotypically diverse population of CPE isolates utilizing the E-mail address: [email protected] (D.P. Nicolau). GDS cross method. https://doi.org/10.1016/j.diagmicrobio.2019.05.014 0732-8893/© 2019 Elsevier Inc. All rights reserved. L.M. Avery et al. / Diagnostic Microbiology and Infectious Disease 95 (2019) 216–220 217 2. Materials and methods Table 1 Select resistance mechanisms of carbapenemase-producing Enterobacteriaceae isolates. 2.1. Bacterial isolates and antimicrobial susceptibility testing N (%) Mechanism Citrobacter spp. E. coli E. cloacae Klebsiella spp. In total, 49 CPE isolates were studied, of which 37 were acquired (N =2) (N =8) (N =4) (N = 35)a from the FDA-CDC Antimicrobial Resistance Bank (Atlanta, GA) and 12 KPC 1 (50.0) 2 (25.0) 3 (75.0) 16 (45.7) were selected from the Center for Anti-Infective Research and Develop- NDM 1 (50.0) 6 (75.0) 1 (25.0) 14 (40.0) ment isolate library. Fosfomycin, aztreonam, cefepime, ceftazidime, cef- OXA-CP 0 (0.0) 0 (0.0) 0 (0.0) 5 (14.3) tazidime/avibactam, ceftolozane/tazobactam, meropenem, and VIM 0 (0.0) 0 (0.0) 0 (0.0) 3 (8.6) b tobramycin MICs were determined by Etest® (bioMérieux, Durham, ESBL 1 (50.0) 5 (62.5) 3 (75.0) 31 (88.6) fosA 0 (0.0) 0 (0.0)c 0 (0.0) 11 (44.0)d NC) in accordance with the manufacturer's instructions. Fosfomycin MICs were determined in duplicate, and in cases of discordance, the ESBL = extended spectrum β-lactamase; KPC = K. pneumoniae carbapenemase; NDM = New Delhi metallo-β-lactamase; OXA-CP = OXA-type carbapenemase. procedure was performed until a modal MIC was evident. MIC Test a fi Includes K. pneumoniae (N = 34) and K. ozaenae (N =1). Strip (Lio lchem®, Waltham, MA) was used to determine piperacillin/ b ESBL-positive isolate contained CTX-M-15 and/or SHV-12. tazobactam MICs due to lack of availability of the Etest product. For c Presence of fosA mutation not assessed in 2 E. coli isolates; fosfomycin GDS MICs were MIC and synergy assessments, P. aeruginosa ATCC 27853 was used as a 1 mg/L and 2 mg/L for these strains. d quality control organism, which is appropriate for extended spectrum Presence of fosA mutation not assessed in 10 K. pneumoniae isolates; among these 10, ≥ β – a total of 4 isolates displayed fosfomycin MICs 64 mg/L (high off-scale GDS MICs -lactamase (ESBL) producing Enterobacteriaceae according to the ≥1024 mg/L were observed in 3 of these 4 strains). manufacturer's instructions. 3.2. Antibiotic interaction assessments 2.2. Antibiotic interaction assessments Among 364 total fosfomycin–antibiotic combinations assessed, the For assessments of antibiotic interaction using GDS methodology, most frequent type of interaction observed was indifference (284/364, isolates were prepared in accordance to the manufacturer's instructions 77.8%, Table 3). This observation is reflected in the geometric mean for antimicrobial susceptibility testing of single agents. Each bacterial FICI for each fosfomycin–antibiotic combination as each value is N1.00. inoculum was prepared to a concentration of 1 to 5 × 108 CFU/mL Synergy with fosfomycin was observed most frequently with from a second subculture, which was confirmed by performing serial di- ceftolozane/tazobactam (C/T), and additivity was observed most fre- lutions and colony counts on agar media (BD™ Trypticase™ Soy Agar quently with aztreonam. with 5% Sheep Blood, Franklin Lakes, NJ). MICs of the agents in combina- An example of synergy between fosfomycin and aztreonam is shown tion were determined by the GDS cross method (Pankey et al., 2013) in Fig. 1. Antagonistic activity between fosfomycin and any of the 8 an- and used to calculate the FICI of each fosfomycin–antibiotic combina- tibiotics tested was not present in any CPE isolate assessed. tion. Briefly, the bacterial suspension was streaked onto Mueller Hinton When results were categorized by carbapenemase type, fosfomycin II agar (BD™ BBL™, Franklin Lakes, NJ) with a sterile swab to create a plus aztreonam was the only combination to display synergy (4/24, bacterial lawn; for each fosfomycin-antibiotic combination tested, anti- 16.7%) among isolates positive for Ambler class B enzymes (i.e., NDM biotic gradient strips were crossed at a 90° angle at the respective MICs and VIM), as shown in Fig. 2. Furthermore, additivity with aztreonam for each agent. To calculate the FICI, the MIC of each antibiotic in combi- was present in 8 (33.3%) isolates (Fig. 2). nation was divided by the MIC of the antibiotic alone, and the results Among KPC-positive isolates, synergy with C/T was observed in 7 were added together. In the
Load more

Recommended publications
  • Efficacy of Fosfomycin Trometamol and Cefuroxime Axetil in the Treatment of Kashmir, India Urinary Tract Infections During Pregnancy
    International Journal of Surgery Science 2019; 3(2): 33-35 E-ISSN: 2616-3470 P-ISSN: 2616-3462 © Surgery Science Efficacy of fosfomycin trometamol and cefuroxime axetil www.surgeryscience.com 2019; 3(2): 33-35 in the treatment of UTI during pregnancy: A Received: 18-11-2018 Accepted: 22-12-2018 comparative study Dr. Robindera Kour In Charge Consultant Surgery, Dr. Robindera Kour, Dr. Gurpreet Kour, Dr. Iqbal Singh, Dr. KK Gupta Govt. Hospital Sarwal, Jammu, and Dr. Rajiv Sharma Jammu and Kashmir, India Dr. Gurpreet Kour DOI: https://doi.org/10.33545/surgery.2019.v3.i2a.373 Medical Officer, Acharya Shri Chander College of Medical Abstract Sciences, Jammu, Jammu and Objective: To compare the efficacy of fosfomycin trometamol and cefuroxime axetil in the treatment of Kashmir, India urinary tract infections during pregnancy. Methods: Prospective clinical study was conducted among pregnant women who were followed as part of Dr. Iqbal Singh routine prenatal care at Government Hospital Sarwal, Jammu, India with complaints of lower UTI were Assistant Professor, Public Health assessed. 60 patients were enrolled, divided into 2 equal groups for treatment with single-dose fosfomycin Dentistry, Indira Gandhi Government Dental College, trometamol and 5-day courses of cefuroxime axetil. Follow-up was carried out after 5 weeks. Jammu, Jammu and Kashmir, Results: The treatment groups did not differ significantly in terms of demographics, clinical compliance India rate and adverse effects. But the patients who were taking 5-day courses of cefuroxime axetil showed statistically significant higher cure rate as well as lower recurrence rate as compared to fosfomycin Dr.
    [Show full text]
  • In Vitro Susceptibility of Multi-Drug Resistant Klebsiella Pneumoniae Strains Causing Nosocomial Infections to Fosfomycin. a Comparison of Determination Methods
    pathogens Article In Vitro Susceptibility of Multi-Drug Resistant Klebsiella pneumoniae Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods Beata M ˛aczy´nska 1,* , Justyna Paleczny 1 , Monika Oleksy-Wawrzyniak 1 , Irena Choroszy-Król 2 and Marzenna Bartoszewicz 1 1 Department of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Medical University, 50-367 Wroclaw, Poland; [email protected] (J.P.); [email protected] (M.O.-W.); [email protected] (M.B.) 2 Department of Basic Sciences, Faculty of Health Sciences, Medical University, 50-367 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Introduction: Over the past few decades, Klebsiella pneumoniae strains increased their pathogenicity and antibiotic resistance, thereby becoming a major therapeutic challenge. One of the few available therapeutic options seems to be intravenous fosfomycin. Unfortunately, the determination of sensitivity to fosfomycin performed in hospital laboratories can pose a significant problem. Therefore, the aim of the present research was to evaluate the activity of fosfomycin against clinical, multidrug-resistant Klebsiella pneumoniae strains isolated from nosocomial infections between Citation: M ˛aczy´nska,B.; Paleczny, J.; 2011 and 2020, as well as to evaluate the methods routinely used in hospital laboratories to assess Oleksy-Wawrzyniak, M.; bacterial susceptibility to this antibiotic. Materials and Methods: 43 multidrug-resistant Klebsiella Choroszy-Król, I.; Bartoszewicz, M. strains isolates from various infections were tested. All the strains had ESBL enzymes, and 20 In Vitro Susceptibility of Multi-Drug also showed the presence of carbapenemases. Susceptibility was determined using the diffusion Resistant Klebsiella pneumoniae Strains method (E-test) and the automated system (Phoenix), which were compared with the reference Causing Nosocomial Infections to method (agar dilution).
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • Fosfomycin Resistance in Escherichia Coli Isolates from South Korea and in Vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics
    antibiotics Article Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics Hyeri Seok 1 , Ji Young Choi 2, Yu Mi Wi 3, Dae Won Park 1, Kyong Ran Peck 4 and Kwan Soo Ko 2,* 1 Division of Infectious Diseases, Department of Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea; [email protected] (H.S.); [email protected] (D.W.P.) 2 Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea; [email protected] 3 Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Korea; [email protected] 4 Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-31-299-6223 Received: 17 February 2020; Accepted: 3 March 2020; Published: 6 March 2020 Abstract: We investigated fosfomycin susceptibility in Escherichia coli clinical isolates from South Korea, including community-onset, hospital-onset, and long-term care facility (LTCF)-onset isolates. The resistance mechanisms and genotypes of fosfomycin-resistant isolates were also identified. Finally, the in vitro efficacy of combinations of fosfomycin with other antibiotics were examined in susceptible or extended spectrum β-lactamase (ESBL)-producing E. coli isolates. The fosfomycin resistance rate was 6.7% and was significantly higher in LTCF-onset isolates than community-onset and hospital-onset isolates. Twenty-one sequence types (STs) were identified among 19 fosfomycin-resistant E. coli isolates, showing diverse genotypes. fosA3 was found in only two isolates, and diverse genetic variations were identified in three genes associated with fosfomycin resistance, namely, GlpT, UhpT, and MurA.
    [Show full text]
  • Fosfomycin for Lower Urinary Tract Infections: Comparative Clinical and Cost-Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS Fosfomycin for Lower Urinary Tract Infections: Comparative Clinical and Cost-Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: April 12, 2018 Report Length: 8 Pages Authors: Kelsey Seal, Caitlyn Ford Cite As: Fosfomycin for Lower Urinary Tract Infections: Comparative Clinical and Cost-Effectiveness. Ottawa: CADTH; 2018 Apr. (CADTH rapid response report: summary of abstracts). Acknowledgments: Disclaimer: The inf ormation in this document is intended to help Canadian health care decision-makers, health care prof essionals, health sy stems leaders, and policy -makers make well-inf ormed decisions and thereby improv e the quality of health care serv ices. While patients and others may access this document, the document is made av ailable f or inf ormational purposes only and no representations or warranties are made with respect to its f itness f or any particular purpose. The inf ormation in this document should not be used as a substitute f or prof essional medical adv ice or as a substitute f or the application of clinical judgment in respect of the care of a particular patient or other prof essional judgment in any decision-making process. The Canadian Agency f or Drugs and Technologies in Health (CADTH) does not endorse any inf ormation, drugs, therapies, treatments, products, processes, or serv ic es. While care has been taken to ensure that the inf ormation prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was f irst published by CADTH, CADTH does not make any guarantees to that ef f ect.
    [Show full text]
  • Fosfomycin Activity Versus Carbapenem-Resistant Enterobacteriaceae and Vancomycin-Resistant Enterococcus, Detroit, 2008–10
    The Journal of Antibiotics (2013) 66, 625–627 & 2013 Japan Antibiotics Research Association All rights reserved 0021-8820/13 www.nature.com/ja NOTE Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10 Jason M Pogue1,2, Dror Marchaim2,3,4, Odaliz Abreu-Lanfranco2, Bharath Sunkara2, Ryan P Mynatt1, Jing J Zhao1, Suchitha Bheemreddy2, Kayoko Hayakawa2, Emily T Martin1, Sorabh Dhar2, Keith S Kaye2 and Paul R Lephart5 The Journal of Antibiotics (2013) 66, 625–627; doi:10.1038/ja.2013.56; published online 29 May 2013 Keywords: CRE; HAI; multidrug resistant; UTI; VRE; in-vitro Enterobacteriaceae and enterococci are among the most common culture coupled with potential clinical signs of infection such as causes of urinary tract infections (UTI) in adults.1 Carbapenem- mental status changes. In these scenarios, when CRE or VRE are the resistant Enterobacteriaceae (CRE) and vancomycin-resistant offending pathogens, often in elderly incontinent institutionalized Enterococcus (VRE) are multidrug-resistant (MDR) pathogens, individuals,12,13 patients are hospitalized and treated with intravenous which have become endemic in many locations worldwide.2,3 These (IV) broad-spectrum and sometime toxic agents, owing to lack of oral pathogens are associated with devastating outcomes among patients regimens. If these patients could have been managed in the outpatient and their continued dissemination and spread pose a threat to public settings, both the patients and the acute-care facilities
    [Show full text]
  • Fosfomycin Drug Review
    THE NEBRASKA MEDICAL CENTER FOSFOMYCIN: REVIEW AND USE CRITERIA BACKGROUND Fosfomycin is a phosphonic acid derivative, which inhibits peptidoglycan assembly, thereby disrupting cell wall synthesis.1 Its uptake into the bacterial cell occurs via active transport, by the L-α-glycerophosphate transport and hexose phosphate uptake systems. Once inside the bacteria, it competes with phosphoenolpyruvate to irreversibly inhibit the enzyme enolpyruvyl transferase that catalyzes the first step of peptidoglycan synthesis.1,2 By irreversibly blocking this enzyme, cell wall synthesis is interrupted. Fosfomycin also decreases bacteria adherence to uroepithelial cells. Fosfomycin has been approved by the Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (UTI) in adult women that is caused by Escherichia coli and Enterococcus faecalis.2 Oral fosfomycin has also been used for non-FDA approved indication such as complicated UTI without bacteremia. Intravenous fosfomycin, which is not available in the US, has also been used for a variety of infections including meningitis, pneumonia, and pyelonephritis.2 Fosfomycin does not have an indication for the treatment of pyelonephritis or perinephric abscess.2,3 Fosfomycin has broad spectrum of activity against aerobic gram positive and gram negative pathogens. It was shown in vitro and in clinical studies, to have activity against ≥90% of strains of E. coli, Citrobacter diversus, C. freundii, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, P. vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, E. faecalis and E. faecium [including vancomycin resistant (VRE)] species, and Staphylococcus aureus [including Methicillin resistant Staphylococcus aureus (MRSA)] associated with UTI.2,3 Currently, the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints exist only for E.
    [Show full text]
  • Urinary Tract Infection (Catheter- Associated): Antimicrobial Prescribing NICE Guideline Draft for Consultation, May 2018
    DRAFT FOR CONSULTATION Urinary tract infection (catheter- associated): antimicrobial prescribing NICE guideline Draft for consultation, May 2018 This guideline sets out an antimicrobial prescribing strategy for catheter- associated urinary tract infection. It aims to optimise antibiotic use and reduce antibiotic resistance. See a 3-page visual summary of the recommendations, including tables to support prescribing decisions. Who is it for? Health professionals People with catheter-associated urinary tract infections, their families and carers The guideline contains: the draft recommendations summary of the evidence. Information about how the guideline was developed is on the guideline’s page on the NICE website. This includes the full evidence review, details of the committee and any declarations of interest. Recommendations The recommendations in this guideline are for preventing and managing urinary tract infection (UTI) in adults, young people and children with a catheter. Urinary tract infection (catheter-associated): antimicrobial prescribing guidance Page 1 of 23 DRAFT FOR CONSULTATION 1.1 Managing catheter-associated urinary tract infection 1.1.1 Be aware that: catheter-associated UTI occurs when bacteria in a catheter bypass the body’s defence mechanisms (such as the urethra and the passing of urine) and enter the bladder the longer a catheter is in place, the more likely bacteria will be found in the urine treatment is only needed for symptomatic catheter-associated UTI not asymptomatic bacteriuria (apart from in pregnant women with asymptomatic bacteriuria, see the NICE antimicrobial prescribing guideline on lower UTI). 1.1.2 Consider removing or changing the catheter before treating the infection if it has been in place for more than 7 days.
    [Show full text]
  • The Susceptibility to Fosfomycin of Gram-Negative Bacteria Isolates from Urinary Tract Infection in the Czech Republic
    Fajfr et al. BMC Urology (2017) 17:33 DOI 10.1186/s12894-017-0222-6 RESEARCH ARTICLE Open Access The susceptibility to fosfomycin of Gram- negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study Miroslav Fajfr1,2*, Miroslav Louda2,3, Pavla Paterová1,2, Lenka Ryšková1,2, Jaroslav Pacovský2,3, Josef Košina2,3, Helena Žemličková1,2 and Miloš Broďák2,3 Abstract Background: Against a background of rapid increase of β-lactamase-producing or multi-resistant pathogenic bacteria and the resulting lack of effective antibiotic treatment, some older antibiotics have been tested for new therapeutic uses. One of these is fosfomycin, to which according to studies these resistant bacteria are very sensitive. Our study was designed because there is no data on the fosfomycin susceptibility rate in the Czech Republic. Method: In this study from January 2013 to June 2014 3295 unique isolates of Gram-negative bacteria which had caused urinary tract infections were examined. The antibiotic susceptibility was measured by disk diffusion test. Both EUCAST and CLSI guidelines criteria (for fosfomycin only) were used for the antibiotic susceptibility evaluation. Results: The most frequently tested bacterial isolates were Escherichia coli (51.3%, n = 1703), Klebsiella pneumoniae (19.4%, n = 643) and Proteus spp. (11.8%, n = 392). Among all isolates 29.0% (n = 963) were resistant to fluoroquinolones, 11.3% (n = 374) produced extended spectrum β-lactamase and 4.2% (n = 141) produced AmpC β-lactamase. The overall in vitro susceptibility was significantly higher for fosfomycin compared to the other tested per-oral antibiotics (nitrofurantoin, ampicillin, co-trimoxazole, ciprofloxacin and cefuroxime) against all tested Gram- negative rod isolates (excluding Morganella morgani and Acinetobacter spp.
    [Show full text]
  • Off-Label Use of Ceftaroline Fosamil: a Systematic Review
    International Journal of Antimicrobial Agents 54 (2019) 562–571 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: www.elsevier.com/locate/ijantimicag Review Off-label use of ceftaroline fosamil: A systematic review ∗ Arianna Pani a,e, , Fabrizio Colombo b, Francesca Agnelli b, Viviana Frantellizzi c, Francesco Baratta d, Daniele Pastori d, Francesco Scaglione a,e a Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Italy b Internal Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy c Department of Radiological, Oncological and Anatomical Pathological Sciences, University of Rome Sapienza, Italy d Department of Internal Medicine and Medical Specialties, University of Rome Sapienza, Italy e Department of Oncology and Onco-Hematology, Postgraduate School of Clinical Pharmacology and Toxicology University of Milan Statale, Italy a r t i c l e i n f o a b s t r a c t Article history: Ceftaroline fosamil is a fifth-generation cephalosporin with anti-methicillin-resistant Staphylococcus au- Received 14 December 2018 reus (MRSA) activity. It has been approved by the EMA and FDA for the treatment of adults and children Accepted 28 June 2019 with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure in- fections (ABSSSI). However, ceftaroline fosamil has a broad spectrum of activity, and a good safety and Editor: Stefania Stefani tolerability profile, so is frequently used off-label. The aim of this systematic review was to summarize the safety and efficacy of off-label use of cef- Keywords: Ceftaroline fosamil taroline. MRSA The review was conducted according to PRISMA guidelines. MEDLINE, EMBASE and CENTRAL Bacteremia databases (2010-2018) were searched using as the main term ceftaroline fosamil and its synonyms in Endocarditis combination with names of infectious diseases of interest.
    [Show full text]
  • Synergy of Fosfomycin with Other Antibiotics for Gram-Positive and Gram-Negative Bacteria Antonia C
    Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria Antonia C. Kastoris, Petros I. Rafailidis, Evridiki K. Vouloumanou, Ioannis D. Gkegkes, Matthew E. Falagas To cite this version: Antonia C. Kastoris, Petros I. Rafailidis, Evridiki K. Vouloumanou, Ioannis D. Gkegkes, Matthew E. Falagas. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. European Journal of Clinical Pharmacology, Springer Verlag, 2010, 66 (4), pp.359-368. 10.1007/s00228-010-0794-5. hal-00570019 HAL Id: hal-00570019 https://hal.archives-ouvertes.fr/hal-00570019 Submitted on 26 Feb 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2010) 66:359–368 DOI 10.1007/s00228-010-0794-5 PHARMACODYNAMICS Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria Antonia C. Kastoris & Petros I. Rafailidis & Evridiki K. Vouloumanou & Ioannis D. Gkegkes & Matthew E. Falagas Received: 24 August 2009 /Accepted: 26 January 2010 /Published online: 26 February 2010 # Springer-Verlag 2010 Abstract with other antibiotics. Yet, in the 27 studies providing data for Background The alarming increase in drug resistance and Gram-positive strains (16 for Staphylococcus aureus, 3 for decreased production of new antibiotics necessitate the coagulase-negative staphylococci, 5 for Streptococcus evaluation of combinations of existing antibiotics.
    [Show full text]
  • Daptomycin in Vitro Activity Against Methicillin-Resistant Staphylococcus
    University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2013 Daptomycin in vitro activity against methicillin- resistant staphylococcus aureus is enhanced by D- cycloserine in a mechanism associated with a decrease in cell surface charge O Gasch Beth Israel Deaconess Medical Center S K. Pillai Beth Israel Deaconess Medical Center J Dakos Beth Israel Deaconess Medical Center Spiros Miyakis University of Wollongong, [email protected] R C. Moellering Beth Israel Deaconess Medical Center See next page for additional authors Publication Details Gasch, O., Pillai, S. K., Dakos, J., Miyakis, S., Moellering, R. C. & Eliopoulos, G. M. (2013). Daptomycin in vitro activity against methicillin-resistant staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge. Antimicrobial Agents and Chemotherapy, 57 (9), 4537-4539. Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Daptomycin in vitro activity against methicillin-resistant staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge Abstract The killing activity of daptomycin against an isogenic pair of daptomycin-susceptible and daptomycin- nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) strains was enhanced by the addition of certain cell wall agents at 1× MIC. However, when high inocula of the DNS strain were used, no significant killing was observed in our experiments. Cytochrome c binding assays revealed d-cycloserine as the only agent associated with a reduction in the cell surface charge for both strains at the concentrations used.
    [Show full text]